Stay updated on Tepotinib & Gefitinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.

Latest updates to the Tepotinib & Gefitinib in NSCLC Clinical Trial page
- Check3 days agoChange DetectedTaoyuan, Taiwan has been added as a site and Taoyuan District, Taiwan has been removed from the study locations. This updates the geographic footprint of the trial sites for INSIGHT.SummaryDifference0.0%

- Check10 days agoChange DetectedThe page’s footer “Revision” has been updated from v3.5.2 to v3.5.3, indicating a platform/version change rather than a change to the trial’s published information.SummaryDifference0.0%

- Check17 days agoChange DetectedSystem revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check46 days agoChange DetectedSite revision updated to v3.5.0, replacing the prior v3.4.3.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision: v3.4.3 replaces v3.4.2.SummaryDifference0.0%

- Check82 days agoChange DetectedThe page revision history shows removal of v3.4.1 and addition of v3.4.2; there are no changes to the study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Tepotinib & Gefitinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.